COMPANY
SHENZHEN READLINE BIOTECH CO LTD
SHENZHEN READLINE BIOTECH CO LTD: API manufacturer for Semaglutide, Tirzepatide, as stated by public registers.
API MANUFACTURER
Filed a drug master file with FDA for the active ingredient.
| Semaglutide | DMF 39791, type II, active, submitted 2024-04-23 Regulator FDA drug master file list |
|---|---|
| Semaglutide | DMF 41076, type II, active, submitted 2025-01-05 Regulator FDA drug master file list |
| Semaglutide | DMF 41906, type II, active, submitted 2025-05-19 Regulator FDA drug master file list |
| Tirzepatide | DMF 41461, type II, active, submitted 2025-03-16 Regulator FDA drug master file list |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.